echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Effect of peripheral CB 1 receptor antagonist JD5037 in the use of the AMPK-activated agent metformin monotherapy and multipharmacy in a rat model of pulmonary hypertension induced by wild lily

    Effect of peripheral CB 1 receptor antagonist JD5037 in the use of the AMPK-activated agent metformin monotherapy and multipharmacy in a rat model of pulmonary hypertension induced by wild lily

    • Last Update: 2022-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Pulmonary hypertension (PH) is a rare disease characterized by an increase in pulmonary artery pressure of more than 25 mmHg at rest, leading to right-sided heart failure and premature death


    AMPK is a cellular energy state sensor that senses low cellular adenosine triphosphate (ATP) concentrations (e.


    Today, the gold standard for PAH therapy is early combination therapy with compounds that affect different pharmacological targets


    The current study evaluated the effect of the peripheral cannabinoid CB 1 receptor antagonist JD5037 for metformin monotherapy and multidrug therapy in rats with wild lily-based induced mild PH


     

    References:

    Remiszewski P, Pędzińska-Betiuk A, Mińczuk K, Schlicker E, Klimek J, Dzięcioł J, Malinowska B.


     

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.